CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that CAT-5571, a novel activator of autophagy, will be presented as a potential treatment for cystic fibrosis in an oral presentation and two poster presentations at the 30th Annual North American Cystic Fibrosis Conference (NACFC). NACFC is being held October 27 – October 29, 2016, in Orlando, FL, at the Orange County Convention Center.
- Feng Liu, Ph.D., Principal Scientist at Catabasis, will give an oral presentation and a poster presentation titled “CAT-5571 as a Novel and Potent Autophagy Activator that Enhances the Trafficking of the F508DEL-CFTR”. The oral presentation will be 10:20am – 10:30am local time during Workshop Session II on Thursday, October 27, 2016, in the Valencia Ballroom and the poster will be presented during Poster Session I on Thursday, October 27, 2016, from 11:15am – 1:45pm local time in the Valencia Ballroom.
- Tracey Bonfield, Ph.D., Assistant Professor at Case Western Reserve University School of Medicine, will present the poster “CAT-5571 as a Novel Autophagy Activator that Enhances the Clearance of Pseudomonas Aeruginosa” during Poster Session I on Thursday, October 27, 2016, from 11:15am – 1:45pm local time in the Valencia Ballroom.
About CAT-5571
Catabasis is developing CAT-5571 as a
potential unique oral treatment for cystic fibrosis (CF) with potential
effects on both the cystic fibrosis transmembrane conductance regulator
(CFTR) and on the antibacterial clearance of Pseudomonas aeruginosa.
CAT-5571 is a small molecule that activates autophagy, a process that
maintains cellular homeostasis and host defense mechanisms, and is known
to be impaired in CF. Catabasis has shown that CAT-5571, in combination
with lumacaftor/ivacaftor, enhances cell-surface trafficking and
function of CFTR with the F508del mutation. Catabasis has also shown
that CAT-5571 enhances the clearance of Pseudomonas aeruginosa infection
in preclinical models of CF, irrespective of CFTR mutation status.
About Cystic Fibrosis
Cystic fibrosis (CF) is a rare,
chronic, genetic, life-shortening disease that affects over 70,000
patients worldwide, predominantly in the Caucasian population. In CF, a
malfunctioning cystic fibrosis transmembrane conductance regulator
(CFTR) ion channel impairs chloride secretion, with deleterious effects
on multiple organs, and particularly devastating effects on pulmonary,
intestinal and pancreatic function. Patients affected with CF are also
predisposed to respiratory failure caused by persistent lung infections
that are difficult to treat with standard antibiotics. Advancements in
research and treatments have extended the life expectancy for those
living with CF, however there is currently no cure.
About Catabasis
At Catabasis Pharmaceuticals, our mission is
to bring hope and life-changing therapies to patients and their
families. Our SMART (Safely Metabolized And Rationally Targeted) linker
drug discovery platform enables us to engineer molecules that
simultaneously modulate multiple targets in a disease. We are applying
our SMART linker platform to build an internal pipeline of product
candidates for rare diseases and plan to pursue partnerships to develop
additional product candidates. For more information on the Company's
drug discovery platform and pipeline of drug candidates, please visit www.catabasis.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161020005435/en/
